iShares Biotechnology ETF (NASDAQ:IBB) Sets New 1-Year High – What’s Next?

iShares Biotechnology ETF (NASDAQ:IBB)’s stock price reached a new 52-week high on Wednesday . The company traded as high as $175.83 and last traded at $175.2410, with a volume of 313872 shares traded. The stock had previously closed at $171.24.

iShares Biotechnology ETF Stock Performance

The business has a 50-day moving average of $167.18 and a 200 day moving average of $149.16.

iShares Biotechnology ETF Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 19th. Shareholders of record on Tuesday, December 16th were given a $0.1831 dividend. This represents a $0.73 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Tuesday, December 16th. This is an increase from iShares Biotechnology ETF’s previous quarterly dividend of $0.08.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Citigroup Inc. lifted its holdings in shares of iShares Biotechnology ETF by 27.0% during the second quarter. Citigroup Inc. now owns 4,073,967 shares of the financial services provider’s stock worth $515,398,000 after buying an additional 865,823 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of iShares Biotechnology ETF by 313.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock valued at $276,526,000 after acquiring an additional 1,451,820 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in iShares Biotechnology ETF by 27.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,060,048 shares of the financial services provider’s stock worth $153,039,000 after buying an additional 226,852 shares during the period. Jefferies Financial Group Inc. acquired a new stake in iShares Biotechnology ETF in the 3rd quarter valued at $65,083,000. Finally, Barclays PLC increased its stake in shares of iShares Biotechnology ETF by 6.7% during the 3rd quarter. Barclays PLC now owns 416,191 shares of the financial services provider’s stock worth $60,085,000 after purchasing an additional 26,032 shares during the last quarter. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.